Peptide Profile

Kisspeptin

GnRH Regulator and Reproductive Hormone

Research Only10 sources

Overview

Composition

Naturally occurring neuropeptide hormone encoded by the KISS1 gene, with active forms including kisspeptin-54 (primary circulating form in humans), kisspeptin-10, -13, and -14

Mechanism of Action

Acts as the endogenous ligand for the G protein-coupled receptor GPR54 (also known as KISS1R), primarily in the hypothalamus, where it stimulates gonadotropin-releasing hormone (GnRH) neurons, triggering downstream secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary

Primary Effects

Acts as a central reproductive-axis signal, with human studies showing gonadotropin release but indication-specific clinical evidence.

Discovery & Background

Initially identified in 1996 by researchers in Hershey, Pennsylvania (hence "kiss" from the city's nickname), as a metastasis-suppressor gene product (metastin) in melanoma and breast cancer models

Its role in puberty and fertility became clear after KISS1R mutations were linked to hypogonadotropic hypogonadism, shifting the field from cancer biology to reproductive endocrinology.

Investigational, not FDA-approved for therapeutic use; limited large-scale trials

Research Overview

Human studies consistently show activation of the reproductive hormone axis, while therapeutic programs remain early and indication-specific.

01
In men, bolus or infusion reliably increases LH, FSH, and testosterone
02
In women, responses are stronger in the preovulatory phase or in hypogonadal states, with weaker effects in the follicular phase
03
Clinical trials (Phase I/II) tested kisspeptin-10/54 for hypogonadotropic hypogonadism, hypothalamic amenorrhea, infertility (e.g., as an ovulation trigger in IVF to reduce OHSS risk)
04
Small clinical programs have evaluated hyperprolactinemia, delayed puberty, and hypoactive sexual desire disorder (HSDD)
05
Men with low desire showed changes in gonadotropin release, sexual brain processing, and penile tumescence in selected studies
06
Most clinical programs remain small and specialized rather than broad approved indications

Remains investigational, not FDA-approved for therapeutic use

Safety Considerations

Monitoring

LH/FSH levels
Testosterone/estrogen
Ultrasound for ovarian response
Reproductive symptoms
Sexual function markers

Side Effects

Common

Generally well-tolerated
Headache, flushing, or nausea can occur in some study settings
Transient hormonal fluctuations

Rare

Desensitization with chronic use

Contraindications

Limited data; caution in hormone-sensitive conditions
Not approved for broad therapeutic use

Educational Notice

Kisspeptin is a physiologic regulator of the reproductive axis with human evidence for gonadotropin release and selected fertility or sexual-function endpoints. Trial programs remain small and indication-specific, and it lacks broad regulatory approval for therapeutic use. Clinical decisions require qualified medical oversight, especially because responses vary by sex, reproductive phase, and endocrine context.

References